Safety and efficacy of long-term filgotinib treatment in Japanese patients with ulcerative colitis: an interim subgroup analysis of the SELECTION long-term extension study.

Filgotinib demonstrated an acceptable long-term benefit-risk profile in Japanese patients, maintaining and improving symptomatic and HRQoL remission for up to 3 years. Japanese patients had a numerically higher incidence of infections and herpes zoster than the overall SELECTIONLTE population.